Header Logo

Connection

JOHN VIERLING to Double-Blind Method

Back to Details
This is a "connection" page, showing publications JOHN VIERLING has written about Double-Blind Method.
JOHN VIERLING
Connection Strength
0.506
Double-Blind Method
  1. Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016 06; 14(6):903-906.e1.
    View in: PubMed
    Score: 0.092
  2. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Oct; 167(5):1008-1018.e5.
    View in: PubMed
    Score: 0.041
  3. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):783-794.
    View in: PubMed
    Score: 0.040
  4. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):795-805.
    View in: PubMed
    Score: 0.040
  5. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial. Nat Med. 2023 02; 29(2):392-400.
    View in: PubMed
    Score: 0.038
  6. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
    View in: PubMed
    Score: 0.033
  7. Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 10; 2(10):716-726.
    View in: PubMed
    Score: 0.026
  8. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na?ve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct; 42(7):829-44.
    View in: PubMed
    Score: 0.022
  9. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun; 64(6):948-56.
    View in: PubMed
    Score: 0.021
  10. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61(6):1238-46.
    View in: PubMed
    Score: 0.021
  11. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug; 147(2):366-76.e6.
    View in: PubMed
    Score: 0.020
  12. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014 Mar; 59(3):1073-83.
    View in: PubMed
    Score: 0.020
  13. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):524-37.
    View in: PubMed
    Score: 0.019
  14. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23.
    View in: PubMed
    Score: 0.019
  15. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol. 2013 Mar; 58(3):479-87.
    View in: PubMed
    Score: 0.019
  16. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):81-87.e4; quiz e5.
    View in: PubMed
    Score: 0.018
  17. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31; 364(13):1207-17.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.